Psoriatic Arthritis
From the Journals
Western diet promoted skin, joint inflammation in preclinical study
This new study found that WD-fed mice had less microbial diversity than that of mice fed a conventional diet.
From the Journals
HBV screening often incomplete or forgone when starting tocilizumab, tofacitinib
About three-quarters of patients starting either drug in a single health system did not undergo complete hepatitis B virus screening beforehand....
Conference Coverage
Physicians question the future of TNF inhibitors for psoriasis, PsA
Two dermatologists and two rheumatologists debate the merits of using IL-17 and IL-23 inhibitors ahead of TNF inhibitors for the treatment of...
Conference Coverage
COVID-19 vaccine hesitancy still weighs heavy for some rheumatic disease patients
ACR COVID-19 vaccine task force chair Dr. Jeffrey Curtis goes over the latest evidence about COVID-19 vaccination in patients with rheumatic and...
Latest News
‘Gold cards’ allow Texas docs to skip prior authorizations
Through this law, doctors in the state will spend less time getting approvals for treatments for their patients.
Conference Coverage
Patients on methotrexate show T-cell response to Pfizer vaccine
Despite poor antibody response to the mRNA COVID-19 vaccine, cellular immunity was generated in patients taking methotrexate, new research shows...
Conference Coverage
Study spanning 2 decades offers insights into pediatric psoriasis trends
The researchers did not find that obesity was a marker of psoriasis severity in the cohort.
From the Journals
New analysis puts U.S. psoriasis prevalence at 3%
Data from national survey show that no significant change in prevalence has occurred since 2003.
From the Journals
Malignancy risk: Secukinumab shows long-term safety for psoriasis, PsA, ankylosing spondylitis
Malignancy rates were low in a large study of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.
From the Journals
Biologic treatment mitigates PsA risk in psoriasis patients, study finds
Continuous treatment with biologics reduced the risk for psoriatic arthritis in patients with moderate to severe plaque psoriasis, compared with...
Conference Coverage
Secukinumab provides clinical benefit in phase 3 juvenile arthritis trial
Phase 3 trial shows secukinumab is effective for enthesitis-related arthritis and juvenile psoriatic arthritis in children.